SCHEMBL2695461

SCHEMBL2695461

CCOC(=O)C(=O)N1CCC(NC(=O)OC(C)(C)C)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.54
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 2/20 0.49
TSHR P16473 1/20 0.49
CTSK P43235 2/20 0.48
HSD11B1 P28845 3/20 0.46
CYP2C9 P11712 1/20 0.46
EPHX1 P07099 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
NAMPT P43490 1/20 0.43
THRB P10828 1/20 0.43
ATM Q13315 1/20 0.43
KCNA3 P22001 1/20 0.42
BTK Q06187 1/20 0.42
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3447113 0.92 HSD11B1 (0.53) GAAMAPTMEN1KMT2AALDH1A1
SCHEMBL4670545 0.87 THRB (0.56) GAAMEN1KMT2AALDH1A1TSHR
SCHEMBL2692802 0.83 CTSK (0.55) GAACTSKHSD11B1CYP2C9EPHX1
SCHEMBL3187254 0.83 THRB (0.51) MEN1KMT2AALDH1A1TSHRCTSK
SCHEMBL655025 0.82 HSD11B1 (0.62) MEN1KMT2AALDH1A1TSHRCTSK
SCHEMBL655026 0.82 HSD11B1 (0.62) MEN1KMT2AALDH1A1TSHRCTSK
SCHEMBL27172341 0.81 CTSK (0.54) CTSKHSD11B1CYP2C9EPHX1CA1
SCHEMBL17557575 0.81 TSHR (0.55) MEN1KMT2AALDH1A1TSHRCTSK
SCHEMBL17323937 0.80 EPHX2 (0.57) MEN1KMT2AALDH1A1TSHRCTSK
SCHEMBL17889947 0.80 CTSK (0.49) GAAMEN1KMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 GAA 3516/4885MAPT 3286/4885MEN1 1493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.